NCBiotech News

Research Triangle Park-based GeneCentric Therapeutics has acquired a sister precision medicine cancer start-up, Chapel Hill’s Select ImmunoGenomics.

A window of opportunity is opening for qualified Pitt County high school students to take an industry-focused training program after graduation and enter a rewarding, well-paying career in pharmaceutical manufacturing.

North Carolina is a global leader in gene therapy thanks to its renowned workforce development programs and the scientific output of its research universities.

Chapel Hill’s Path BioAnalytics, a precision-medicine company focused on new treatments for respiratory disease, has licensed rights to a cystic fibrosis drug candidate from a Chinese biopharmaceutical company.

Among the fastest-growing young companies in America, 135 of them can be found right here in North Carolina, according to the latest Inc. 5000 list. And Raleigh life science consulting firm Eva Garland Consulting is on the list again.

The growing number of agricultural biotechnology companies and jobs in North Carolina has motivated Alamance Community College in Graham to offer the state’s first and only associate’s degree program in the field.

The North Carolina Biotechnology Center will open the doors to its Conference Center on August 28 so potential clients can get to know its array of hosting amenities.

The 12- county Piedmont Triad region of North Carolina continues to transform itself by investing in infrastructure, talent, and innovation -- and ag tech is a growing part of it.

The BIO World Congress on Industrial Biotechnology and Ag Tech will bring industry thought leaders to North Carolina in 2020, for the first time, a recognition that Raleigh is at the heart of the global ag tech revolution.

Sumani Nunna, a senior at the North Carolina School of Science and Mathematics in Durham, was one of the 15 finalists for the International BioGENEius Challenge, a major science competition for high school students.

Durham-based BioCryst Pharmaceuticals has signed a definitive merger agreement with Idera Pharmaceuticals.

Norris Tolson, president and CEO, made the following statement upon the release of Governor Pat McCrory's budget, March 20, 2013.

A multi-year collaboration to help improve outcomes for patients with head and neck cancer has advanced to a second phase for Research Triangle Park-based GeneCentric Therapeutics, Inc.  

Durham's Heat Biologics has received an FDA go-ahead to start a Phase 1 clinical trial to evaluate combining two of its immune-stimulating cell lines in patients with solid tumors resistant to standard treatment.

Emboldened by a recent cash infusion of $225 million from investors, AskBio has acquired Scottish company Synpromics to help it develop therapeutics for a wider array of genetic disorders than the rare diseases it has targeted to date.